{"protocolSection":{"identificationModule":{"nctId":"NCT03215706","orgStudyIdInfo":{"id":"CA209-9LA"},"secondaryIdInfos":[{"id":"2017-001195-35","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC","officialTitle":"A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer","acronym":"CheckMate 9LA"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-08-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-08-16","type":"ACTUAL"},"completionDateStruct":{"date":"2024-10-18","type":"ACTUAL"},"studyFirstSubmitDate":"2017-07-11","studyFirstSubmitQcDate":"2017-07-11","studyFirstPostDateStruct":{"date":"2017-07-12","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-08-15","resultsFirstSubmitQcDate":"2020-08-31","resultsFirstPostDateStruct":{"date":"2020-09-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-02","lastUpdatePostDateStruct":{"date":"2025-12-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease"},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":719,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Module A","type":"EXPERIMENTAL","description":"Chemotherapy/Biologics combined","interventionNames":["Biological: Ipilimumab","Biological: Nivolumab","Drug: Carboplatin","Drug: Paclitaxel","Drug: Pemetrexed","Drug: Cisplatin"]},{"label":"Module B","type":"ACTIVE_COMPARATOR","description":"Chemotherapy Combination","interventionNames":["Drug: Carboplatin","Drug: Paclitaxel","Drug: Pemetrexed","Drug: Cisplatin"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ipilimumab","description":"Specified dose on specified day","armGroupLabels":["Module A"],"otherNames":["Yervoy, BMS734016"]},{"type":"BIOLOGICAL","name":"Nivolumab","description":"Specified dose on specified day","armGroupLabels":["Module A"],"otherNames":["Opdivo, BMS936558"]},{"type":"DRUG","name":"Carboplatin","description":"Specified dose on specified day","armGroupLabels":["Module A","Module B"]},{"type":"DRUG","name":"Paclitaxel","description":"Specified dose on specified day","armGroupLabels":["Module A","Module B"],"otherNames":["Taxol"]},{"type":"DRUG","name":"Pemetrexed","description":"Specified dose on specified day","armGroupLabels":["Module A","Module B"],"otherNames":["Alimta"]},{"type":"DRUG","name":"Cisplatin","description":"Specified dose on specified day","armGroupLabels":["Module A","Module B"],"otherNames":["Platinol"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","timeFrame":"From date of randomization to date of death (assessed up to October 2019, approximately 23 months)"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS) by BICR","description":"PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)"},{"measure":"Objective Response Rate (ORR) by BICR","description":"ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)"},{"measure":"Duration of Response (DoR)","description":"DoR was defined as the time between the date of first confirmed documented response (CR or PR) to the date of the first documented BICR-assessed tumor progression (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who started subsequent therapy (including palliative local therapy) without a prior reported progression were censored at the last evaluable tumor assessments prior to initiation of the subsequent anticancer therapy (including palliative local therapy). Participants who died without a reported prior progression were considered to have progressed on the date of their death. For subjects who neither progressed nor died, DoR was censored on the date of their last evaluable tumor assessment. DoR was evaluated for responders (confirmed CR or PR) only.","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)"},{"measure":"Time to Response (TTR)","description":"TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)"},{"measure":"Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression","description":"ORR was defined as the proportion of randomized participants with a best overall response (BOR) of confirmed complete or partial response per BICR using RECIST v1.1. BOR was assessed from randomization until documented progression, start of palliative local or subsequent anti-cancer therapy-whichever came first. If none occurred, all response data contributed to BOR. For those treated beyond progression, BOR was based on responses before initial RECIST-defined progression. PD-L1 expression was measured via Dako PD-L1 IHC 28-8 pharmDx test as the percentage of tumor cells with membrane staining among ≥100 evaluable cells. Expression was categorized as ≥1%, \\<1%, not quantifiable, ≥50%, or 1-49%.","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)"},{"measure":"PFS by BICR by PD-L1 Tumor Cell Expression","description":"PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)"},{"measure":"OS by PD-L1 Tumor Cell Expression","description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","timeFrame":"From date of randomization to date of death (assessed up to October 2024, approximately 72 months)"},{"measure":"PFS by BICR by Tumor Mutational Burden","description":"PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)"},{"measure":"ORR by BICR by Tumor Mutational Burden","description":"ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)"},{"measure":"OS by Tumor Mutational Burden","description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","timeFrame":"From date of randomization to date of death (assessed up to October 2024, approximately 72 months)"}]},"eligibilityModule":{"eligibilityCriteria":"For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Participants with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1\n* Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria\n* Participants must have PD-L1 IHC testing with results performed by a central laboratory during the screening period\n\nExclusion Criteria:\n\n* Participants with known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy (including, but not limited to, deletions in exon 19 and exon 21 \\[L858R\\] substitution mutations) are excluded\n* Participants with known anaplastic lymphoma kinase (ALK) translocations which are sensitive to available targeted inhibitor therapy are excluded\n* Participants with untreated CNS metastases are excluded. Participants are eligible if CNS metastases are adequately treated and participants are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to first treatment\n\nOther protocol inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Memorial Health Systems","city":"Colorado Springs","state":"Colorado","zip":"80909","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Local Institution - 0044","city":"Plainville","state":"Connecticut","zip":"06062","country":"United States","geoPoint":{"lat":41.67454,"lon":-72.85816}},{"facility":"Local Institution - 0045","city":"Jacksonville","state":"Florida","zip":"32207","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Local Institution - 0029","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Local Institution - 0091","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Local Institution - 0004","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Local Institution - 0105","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Local Institution - 0058","city":"Johnson City","state":"New York","zip":"13790","country":"United States","geoPoint":{"lat":42.11563,"lon":-75.95881}},{"facility":"Local Institution - 0098","city":"Mineola","state":"New York","zip":"11501","country":"United States","geoPoint":{"lat":40.74927,"lon":-73.64068}},{"facility":"Local Institution - 0095","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Local Institution - 0006","city":"Lancaster","state":"Pennsylvania","zip":"17602","country":"United States","geoPoint":{"lat":40.03788,"lon":-76.30551}},{"facility":"Local Institution - 0047","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Local Institution - 0093","city":"Pittsburgh","state":"Pennsylvania","zip":"15224","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Local Institution - 0094","city":"Charleston","state":"South Carolina","zip":"29414","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Southwest Regional Cancer Clinic","city":"St. George","state":"Utah","zip":"84770","country":"United States","geoPoint":{"lat":37.10415,"lon":-113.58412}},{"facility":"Local Institution - 0099","city":"Madison","state":"Wisconsin","zip":"53705","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"Local Institution - 0014","city":"Ciudad Autónoma de Buenos Aires","state":"Buenos Aires","zip":"C1426ANZ","country":"Argentina"},{"facility":"Local Institution - 0028","city":"Río Cuarto","state":"Córdoba Province","zip":"5800","country":"Argentina","geoPoint":{"lat":-33.13044,"lon":-64.35272}},{"facility":"Local Institution - 0026","city":"Viedma","state":"Río Negro Province","zip":"8500","country":"Argentina","geoPoint":{"lat":-40.81519,"lon":-63.0004}},{"facility":"Local Institution - 0027","city":"Rosario","state":"Santa Fe Province","zip":"S2000DSV","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Local Institution - 0030","city":"Córdoba","zip":"5000","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Local Institution - 0086","city":"Gosford","state":"New South Wales","zip":"2250","country":"Australia","geoPoint":{"lat":-33.4244,"lon":151.34399}},{"facility":"Local Institution - 0040","city":"Bedford Park","state":"South Australia","zip":"5042","country":"Australia","geoPoint":{"lat":-35.02204,"lon":138.56815}},{"facility":"Local Institution - 0089","city":"Box Hill","state":"Victoria","zip":"3128","country":"Australia","geoPoint":{"lat":-37.81887,"lon":145.12545}},{"facility":"Local Institution - 0036","city":"Heidelberg","state":"Victoria","zip":"3084","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}},{"facility":"Local Institution - 0078","city":"Murdoch","state":"Western Australia","zip":"6150","country":"Australia","geoPoint":{"lat":-32.06987,"lon":115.83757}},{"facility":"Local Institution - 0002","city":"Gilly","zip":"6060","country":"Belgium","geoPoint":{"lat":50.42449,"lon":4.4789}},{"facility":"Local Institution - 0033","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"Local Institution - 0001","city":"Roeselare","zip":"8800","country":"Belgium","geoPoint":{"lat":50.94653,"lon":3.12269}},{"facility":"Local Institution - 0068","city":"Natal","state":"Rio Grande do Norte","zip":"59075-740","country":"Brazil","geoPoint":{"lat":-5.795,"lon":-35.20944}},{"facility":"Local Institution - 0063","city":"Ijuí","state":"Rio Grande do Sul","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Local Institution - 0067","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Local Institution - 0069","city":"Blumenau","state":"Santa Catarina","zip":"89010-340","country":"Brazil","geoPoint":{"lat":-26.91944,"lon":-49.06611}},{"facility":"Local Institution - 0064","city":"Barretos","state":"São Paulo","zip":"14780-070","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Local Institution - 0065","city":"São José do Rio Preto","state":"São Paulo","zip":"15090-000","country":"Brazil","geoPoint":{"lat":-20.81972,"lon":-49.37944}},{"facility":"Local Institution - 0066","city":"Rio de Janeiro","zip":"20231-050","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Local Institution - 0070","city":"São Paulo","zip":"01327-001","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Local Institution - 0090","city":"Montreal","state":"Quebec","zip":"H1T 2M4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Local Institution - 0083","city":"Montreal","state":"Quebec","zip":"H3T 1E2","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Local Institution - 0082","city":"Montreal","state":"Quebec","zip":"H4A 3J1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Local Institution - 0080","city":"Rimouski","state":"Quebec","zip":"G5L 5T1","country":"Canada","geoPoint":{"lat":48.44879,"lon":-68.52396}},{"facility":"Local Institution - 0079","city":"Viña del Mar","state":"Región de Valparaíso","zip":"2520612","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Local Institution - 0059","city":"Santiago","state":"Santiago Metropolitan","zip":"7500921","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0084","city":"Santiago","state":"Santiago Metropolitan","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0139","city":"Beijing","state":"BEI","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Local Institution - 0146","city":"Haikou","state":"Hainan","zip":"570311","country":"China","geoPoint":{"lat":20.03421,"lon":110.34651}},{"facility":"Local Institution - 0148","city":"Zhengzhou","state":"Henan","zip":"450003","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Local Institution - 0120","city":"Zhengzhou","state":"Henan","zip":"450052","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Local Institution - 0144","city":"Changsha","state":"Hunan","zip":"410000","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Local Institution - 0106","city":"Changchun","state":"Jilin","zip":"130012","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Local Institution - 0108","city":"Xi'an","state":"Shan3xi","zip":"710038","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Local Institution - 0110","city":"Hangzhou","state":"Zhejiang","zip":"310016","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Local Institution - 0111","city":"Zhejiang","state":"Zhejiang","zip":"310022","country":"China"},{"facility":"Local Institution - 0113","city":"Beijing","zip":"102206","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Local Institution - 0112","city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Local Institution - 0010","city":"Bron","state":"Auvergne-Rhône-Alpes","zip":"69500","country":"France","geoPoint":{"lat":45.73865,"lon":4.91303}},{"facility":"Local Institution - 0009","city":"Lyon Cedex08","state":"Auvergne-Rhône-Alpes","zip":"69373","country":"France"},{"facility":"Local Institution - 0013","city":"Caen","zip":"14033","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Local Institution - 0071","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Local Institution - 0012","city":"Montpellier","zip":"34295","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Local Institution - 0035","city":"Nantes","zip":"44093","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Local Institution - 0011","city":"Paris","zip":"75970","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution - 0097","city":"Saint-Brieuc","zip":"22027","country":"France","geoPoint":{"lat":48.51513,"lon":-2.76838}},{"facility":"Local Institution - 0073","city":"Berlin","zip":"14165","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Local Institution - 0016","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Local Institution - 0072","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Local Institution - 0019","city":"Hemer","zip":"58675","country":"Germany","geoPoint":{"lat":51.38707,"lon":7.77019}},{"facility":"Local Institution - 0017","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"Local Institution - 0074","city":"Magdeburg","zip":"39120","country":"Germany","geoPoint":{"lat":52.13129,"lon":11.63189}},{"facility":"Local Institution - 0015","city":"München","zip":"81925","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Local Institution - 0018","city":"Stuttgart","zip":"70376","country":"Germany","geoPoint":{"lat":48.78232,"lon":9.17702}},{"facility":"Local Institution - 0021","city":"Dublin","zip":"8","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Local Institution - 0020","city":"Limerick","zip":"V94 F858","country":"Ireland","geoPoint":{"lat":52.66472,"lon":-8.62306}},{"facility":"Local Institution - 0042","city":"Lucca","zip":"5510","country":"Italy","geoPoint":{"lat":43.84369,"lon":10.50447}},{"facility":"Local Institution - 0041","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Local Institution - 0043","city":"Napoli","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Local Institution - 0101","city":"Fukushima","state":"Fukushima","zip":"9601295","country":"Japan","geoPoint":{"lat":37.75,"lon":140.46667}},{"facility":"Local Institution - 0118","city":"Maebashi","state":"Gunma","zip":"3718511","country":"Japan","geoPoint":{"lat":36.4,"lon":139.08333}},{"facility":"Local Institution - 0128","city":"Ota-shi","state":"Gunma","zip":"3738550","country":"Japan"},{"facility":"Local Institution - 0138","city":"Hiroshima","state":"Hiroshima","zip":"7308518","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Local Institution - 0137","city":"Hiroshima","state":"Hiroshima","zip":"7348511","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Local Institution - 0127","city":"Sapporo","state":"Hokkaido","zip":"0608648","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Local Institution - 0131","city":"Akashi-shi","state":"Hyōgo","zip":"6738558","country":"Japan"},{"facility":"Local Institution - 0119","city":"Himeji-shi","state":"Hyōgo","zip":"6708520","country":"Japan"},{"facility":"Local Institution - 0104","city":"Kobe","state":"Hyōgo","zip":"6500047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Local Institution - 0115","city":"Kanazawa","state":"Ishikawa-ken","zip":"9208641","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Local Institution - 0100","city":"Shiwa-gun","state":"Iwate","zip":"0283695","country":"Japan"},{"facility":"Local Institution - 0129","city":"Yokohama","state":"Kanagawa","zip":"2210855","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Local Institution - 0114","city":"Yokohama","state":"Kanagawa","zip":"2360051","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Local Institution - 0134","city":"Yokohama","state":"Kanagawa","zip":"2418515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Local Institution - 0116","city":"Niigata","state":"Niigata","zip":"9518566","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Local Institution - 0136","city":"Okayama","state":"Okayama-ken","zip":"7008558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Local Institution - 0135","city":"Habikino-shi","state":"Osaka","zip":"5838588","country":"Japan"},{"facility":"Local Institution - 0103","city":"Ōsaka-sayama","state":"Osaka","zip":"5898511","country":"Japan","geoPoint":{"lat":34.49524,"lon":135.55069}},{"facility":"Local Institution - 0102","city":"Kitaadachi-gun","state":"Saitama","zip":"3620806","country":"Japan"},{"facility":"Local Institution - 0132","city":"Ube-shi","state":"Yamaguchi","zip":"7550241","country":"Japan"},{"facility":"Local Institution - 0130","city":"Osaka","zip":"545-8586","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Local Institution - 0077","city":"La Paz","state":"BAJA Californa SUR","zip":"23040","country":"Mexico","geoPoint":{"lat":24.14231,"lon":-110.31316}},{"facility":"Local Institution - 0061","city":"Guadalajara","state":"Jalisco","zip":"44280","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"Local Institution - 0075","city":"Veracruz, Veracruz","zip":"91900","country":"Mexico"},{"facility":"Local Institution - 0087","city":"Bydgoszcz","zip":"85-796","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Local Institution - 0022","city":"Bytom","zip":"41-902","country":"Poland","geoPoint":{"lat":50.34802,"lon":18.93282}},{"facility":"Local Institution - 0085","city":"Gdansk","zip":"80-952","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Local Institution - 0034","city":"Bucharest","zip":"020122","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Local Institution - 0031","city":"Cluj-Napoca","zip":"400015","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Local Institution - 0032","city":"Craiova","zip":"200542","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Local Institution - 0024","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Local Institution - 0025","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Local Institution - 0054","city":"A Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Local Institution - 0053","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0052","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0055","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Local Institution - 0056","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Local Institution - 0050","city":"Guildford","zip":"GU2 7XX","country":"United Kingdom","geoPoint":{"lat":51.23536,"lon":-0.57427}},{"facility":"Local Institution - 0049","city":"London","zip":"SE1 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Local Institution - 0048","city":"Tauton","zip":"TA1 5DA","country":"United Kingdom"}]},"referencesModule":{"references":[{"pmid":"39369790","type":"DERIVED","citation":"Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Bernabe Caro R, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. J Thorac Oncol. 2025 Jan;20(1):94-108. doi: 10.1016/j.jtho.2024.09.1439. Epub 2024 Oct 4."},{"pmid":"39270380","type":"DERIVED","citation":"Reck M, Ciuleanu TE, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, Reinmuth N, Richardet E, Felip E, Menezes J, Cheng Y, Mizutani H, Zurawski B, Alexandru A, Carbone DP, Lu S, John T, Aoyama T, Grootendorst DJ, Hu N, Eccles LJ, Paz-Ares LG. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024 Nov;211:114296. doi: 10.1016/j.ejca.2024.114296. Epub 2024 Aug 25."},{"pmid":"33476593","type":"DERIVED","citation":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Perol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18."}],"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"http://www.BMSClinicalTrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"707 Randomized and treated","groups":[{"id":"FG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"FG001","title":"Treatment B","description":"Chemotherapy only"}],"periods":[{"title":"Randomization","milestones":[{"type":"STARTED","comment":"= Participants Randomized","achievements":[{"groupId":"FG000","numSubjects":"361"},{"groupId":"FG001","numSubjects":"358"}]},{"type":"COMPLETED","comment":"= Participants treated","achievements":[{"groupId":"FG000","numSubjects":"358"},{"groupId":"FG001","numSubjects":"349"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Adverse Event unrelated to study drug","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"participant withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"no longer meets study criteria","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"other reasons","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]}]},{"title":"Treatment Period","milestones":[{"type":"STARTED","comment":"= Participants treated","achievements":[{"groupId":"FG000","numSubjects":"358"},{"groupId":"FG001","numSubjects":"349"}]},{"type":"COMPLETED","comment":"= completing treatment","achievements":[{"groupId":"FG000","numSubjects":"49"},{"groupId":"FG001","numSubjects":"100"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"309"},{"groupId":"FG001","numSubjects":"249"}]}],"dropWithdraws":[{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"184"},{"groupId":"FG001","numSubjects":"174"}]},{"type":"Study Drug Toxicity","reasons":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"24"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse event unrelated to study drug","reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"Request to D/C treatment","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Participant withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Administrative reason by sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"other reasons","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Not reported","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"BG001","title":"Treatment B","description":"Chemotherapy only"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"361"},{"groupId":"BG001","value":"358"},{"groupId":"BG002","value":"719"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.0","spread":"8.3"},{"groupId":"BG001","value":"65.0","spread":"10.3"},{"groupId":"BG002","value":"65.0","spread":"9.4"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Count of Participants","classes":[{"title":"˂65 years old","categories":[{"measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"178"},{"groupId":"BG002","value":"49.2"}]}]},{"title":"≥65 and ˂75 years old","categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"147"},{"groupId":"BG002","value":"41.0"}]}]},{"title":"≥75 years old","categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"9.7"}]}]},{"title":"≥85 years old","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"215"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"252"},{"groupId":"BG001","value":"252"},{"groupId":"BG002","value":"504"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"60"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"158"},{"groupId":"BG002","value":"312"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"169"},{"groupId":"BG002","value":"347"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"60"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"322"},{"groupId":"BG001","value":"316"},{"groupId":"BG002","value":"638"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"11"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization to date of death (assessed up to October 2019, approximately 23 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.13","lowerLimit":"13.24","upperLimit":"16.16"},{"groupId":"OG001","value":"10.74","lowerLimit":"9.46","upperLimit":"12.45"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Treatment A over Treatment B","pValue":"0.0006","statisticalMethod":"Log-rank test stratified","paramType":"Hazard Ratio (HR)","paramValue":"0.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.56","ciUpperLimit":"0.86"}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) by BICR","description":"PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.74","lowerLimit":"5.55","upperLimit":"8.05"},{"groupId":"OG001","value":"5.26","lowerLimit":"4.37","upperLimit":"5.59"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Treatment A over Treatment B","statisticalMethod":"Log-rank test stratified","paramType":"Hazard Ratio (HR)","paramValue":"0.70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"0.82"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) by BICR","description":"ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","lowerLimit":"32.9","upperLimit":"43.2"},{"groupId":"OG001","value":"25.1","lowerLimit":"20.7","upperLimit":"30.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Treatment A over Treatment B","statisticalMethod":"Mantel Haenszel","paramType":"Odds Ratio (OR)","paramValue":"12.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"6.0","ciUpperLimit":"19.4"}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR was defined as the time between the date of first confirmed documented response (CR or PR) to the date of the first documented BICR-assessed tumor progression (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who started subsequent therapy (including palliative local therapy) without a prior reported progression were censored at the last evaluable tumor assessments prior to initiation of the subsequent anticancer therapy (including palliative local therapy). Participants who died without a reported prior progression were considered to have progressed on the date of their death. For subjects who neither progressed nor died, DoR was censored on the date of their last evaluable tumor assessment. DoR was evaluated for responders (confirmed CR or PR) only.","populationDescription":"All confirmed Responders, Global Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"90"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.01","lowerLimit":"8.71","upperLimit":"20.21"},{"groupId":"OG001","value":"5.59","lowerLimit":"4.37","upperLimit":"7.10"}]}]}]},{"type":"SECONDARY","title":"Time to Response (TTR)","description":"TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.","populationDescription":"All Confirmed Responders, Global Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"90"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","lowerLimit":"1.1","upperLimit":"52.1"},{"groupId":"OG001","value":"1.58","lowerLimit":"1.2","upperLimit":"22.2"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression","description":"ORR was defined as the proportion of randomized participants with a best overall response (BOR) of confirmed complete or partial response per BICR using RECIST v1.1. BOR was assessed from randomization until documented progression, start of palliative local or subsequent anti-cancer therapy-whichever came first. If none occurred, all response data contributed to BOR. For those treated beyond progression, BOR was based on responses before initial RECIST-defined progression. PD-L1 expression was measured via Dako PD-L1 IHC 28-8 pharmDx test as the percentage of tumor cells with membrane staining among ≥100 evaluable cells. Expression was categorized as ≥1%, \\<1%, not quantifiable, ≥50%, or 1-49%.","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}]}],"classes":[{"title":"BASELINE PD-L1 EXPRESSION ≥1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"204"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","lowerLimit":"35.8","upperLimit":"49.7"},{"groupId":"OG001","value":"27.5","lowerLimit":"21.5","upperLimit":"34.1"}]}]},{"title":"BASELINE PD-L1 EXPRESSION < 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","lowerLimit":"23.4","upperLimit":"39.6"},{"groupId":"OG001","value":"20.2","lowerLimit":"13.6","upperLimit":"28.1"}]}]},{"title":"Non-Quantifiable PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"17.2","upperLimit":"59.3"},{"groupId":"OG001","value":"32.0","lowerLimit":"14.9","upperLimit":"53.5"}]}]},{"title":"BASELINE PD-L1 EXPRESSION 1 - 49%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.3","lowerLimit":"29.8","upperLimit":"47.3"},{"groupId":"OG001","value":"23.6","lowerLimit":"15.9","upperLimit":"32.8"}]}]},{"title":"BASELINE PD-L1 EXPRESSION >= 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"98"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"38.3","upperLimit":"61.7"},{"groupId":"OG001","value":"31.6","lowerLimit":"22.6","upperLimit":"41.8"}]}]}]},{"type":"SECONDARY","title":"PFS by BICR by PD-L1 Tumor Cell Expression","description":"PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}]}],"classes":[{"title":"< 1% PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.78","lowerLimit":"4.40","upperLimit":"7.66"},{"groupId":"OG001","value":"4.96","lowerLimit":"4.21","upperLimit":"5.78"}]}]},{"title":">= 1% PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"204"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.87","lowerLimit":"5.55","upperLimit":"8.94"},{"groupId":"OG001","value":"4.70","lowerLimit":"4.24","upperLimit":"5.55"}]}]},{"title":"with 1-49% PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.74","lowerLimit":"4.50","upperLimit":"8.51"},{"groupId":"OG001","value":"5.29","lowerLimit":"4.24","upperLimit":"5.68"}]}]},{"title":"with >= 50% PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"98"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.28","lowerLimit":"4.44","upperLimit":"12.48"},{"groupId":"OG001","value":"4.53","lowerLimit":"4.14","upperLimit":"5.65"}]}]},{"title":"Non-Quantifiable PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.95","lowerLimit":"3.61","upperLimit":"15.08"},{"groupId":"OG001","value":"6.77","lowerLimit":"2.83","upperLimit":"13.83"}]}]}]},{"type":"SECONDARY","title":"OS by PD-L1 Tumor Cell Expression","description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","populationDescription":"All Randomized Participants, Global Population with PD-L1 measurements","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization to date of death (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"358"}]}],"classes":[{"title":"< 1% PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.74","lowerLimit":"13.67","upperLimit":"20.27"},{"groupId":"OG001","value":"9.79","lowerLimit":"7.69","upperLimit":"13.54"}]}]},{"title":">= 1% PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"204"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.80","lowerLimit":"13.77","upperLimit":"22.18"},{"groupId":"OG001","value":"10.89","lowerLimit":"9.49","upperLimit":"13.17"}]}]},{"title":"with 1-49% PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.20","lowerLimit":"12.62","upperLimit":"21.22"},{"groupId":"OG001","value":"10.37","lowerLimit":"8.67","upperLimit":"12.35"}]}]},{"title":"with >= 50% PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"98"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.91","lowerLimit":"13.11","upperLimit":"29.11"},{"groupId":"OG001","value":"12.93","lowerLimit":"9.36","upperLimit":"17.58"}]}]},{"title":"Non-Quantifiable PD-L1 Expression","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.84","lowerLimit":"7.16","upperLimit":"15.57"},{"groupId":"OG001","value":"17.05","lowerLimit":"8.64","upperLimit":"NA","comment":"Upper Limit Not Reached"}]}]}]},{"type":"POST_HOC","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization to date of death (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.80","lowerLimit":"13.93","upperLimit":"19.71"},{"groupId":"OG001","value":"10.96","lowerLimit":"9.49","upperLimit":"12.71"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"Treatment A over Treatment B","statisticalMethod":"Stratified Cox proportional hazard model","paramType":"Hazard Ratio (HR)","paramValue":"0.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"0.87"}]},{"type":"SECONDARY","title":"PFS by BICR by Tumor Mutational Burden","description":"PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.","populationDescription":"All Randomized Participants, Global Population with tumor mutational burden measurements","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"356"}]}],"classes":[{"title":"≥ 10 Mutations/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.94","lowerLimit":"5.55","upperLimit":"13.01"},{"groupId":"OG001","value":"4.70","lowerLimit":"4.14","upperLimit":"5.62"}]}]},{"title":"< 10 Mutations/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.62","lowerLimit":"4.17","upperLimit":"7.20"},{"groupId":"OG001","value":"5.16","lowerLimit":"4.21","upperLimit":"5.62"}]}]},{"title":"Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"219"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.37","lowerLimit":"5.36","upperLimit":"8.21"},{"groupId":"OG001","value":"4.96","lowerLimit":"4.27","upperLimit":"5.55"}]}]},{"title":"Not Evaluable","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.74","lowerLimit":"4.24","upperLimit":"9.69"},{"groupId":"OG001","value":"5.45","lowerLimit":"4.17","upperLimit":"5.82"}]}]}]},{"type":"SECONDARY","title":"ORR by BICR by Tumor Mutational Burden","description":"ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.","populationDescription":"All Randomized Participants, Global Population with tumor mutational burden measurements","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"356"}]}],"classes":[{"title":"≥ 10 Mutations/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","lowerLimit":"35.6","upperLimit":"55.8"},{"groupId":"OG001","value":"29.3","lowerLimit":"19.7","upperLimit":"40.4"}]}]},{"title":"< 10 Mutations/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","lowerLimit":"23.9","upperLimit":"40.1"},{"groupId":"OG001","value":"27.0","lowerLimit":"19.8","upperLimit":"35.3"}]}]},{"title":"Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"219"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","lowerLimit":"31.4","upperLimit":"44.1"},{"groupId":"OG001","value":"27.9","lowerLimit":"22.0","upperLimit":"34.3"}]}]},{"title":"Not Evaluable","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"27.8","upperLimit":"45.8"},{"groupId":"OG001","value":"21.2","lowerLimit":"14.7","upperLimit":"29.0"}]}]}]},{"type":"SECONDARY","title":"OS by Tumor Mutational Burden","description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","populationDescription":"All Randomized Participants, Global Population with tumor mutational burden measurements","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of randomization to date of death (assessed up to October 2024, approximately 72 months)","groups":[{"id":"OG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy"},{"id":"OG001","title":"Treatment B","description":"Chemotherapy only"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"356"}]}],"classes":[{"title":"≥ 10 Mutations/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"82"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.05","lowerLimit":"12.45","upperLimit":"20.76"},{"groupId":"OG001","value":"10.76","lowerLimit":"7.85","upperLimit":"15.41"}]}]},{"title":"< 10 Mutations/MB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.51","lowerLimit":"11.99","upperLimit":"19.98"},{"groupId":"OG001","value":"12.55","lowerLimit":"10.38","upperLimit":"14.92"}]}]},{"title":"Overall","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"219"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.57","lowerLimit":"13.34","upperLimit":"19.38"},{"groupId":"OG001","value":"12.06","lowerLimit":"10.35","upperLimit":"14.06"}]}]},{"title":"Not Evaluable","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.10","lowerLimit":"13.47","upperLimit":"25.49"},{"groupId":"OG001","value":"9.46","lowerLimit":"8.15","upperLimit":"11.79"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"30 days after last dose, assessed up to October 2024, approximately 72 months","description":"The number at Risk for All-Cause Mortality represents all Randomized Participants. The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication","eventGroups":[{"id":"EG000","title":"Treatment A","description":"Nivolumab + Ipilimumab + Chemotherapy","deathsNumAffected":304,"deathsNumAtRisk":361,"seriousNumAffected":259,"seriousNumAtRisk":358,"otherNumAffected":343,"otherNumAtRisk":358},{"id":"EG001","title":"Treatment B","description":"Chemotherapy Only","deathsNumAffected":318,"deathsNumAtRisk":358,"seriousNumAffected":197,"seriousNumAtRisk":349,"otherNumAffected":329,"otherNumAtRisk":349}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":358},{"groupId":"EG001","numAffected":18,"numAtRisk":349}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":358},{"groupId":"EG001","numAffected":9,"numAtRisk":349}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":358},{"groupId":"EG001","numAffected":4,"numAtRisk":349}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":5,"numAtRisk":349}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":7,"numAtRisk":349}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":3,"numAtRisk":349}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cardiovascular insufficiency","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Cor pulmonale chronic","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Pericardial effusion malignant","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Ventricular dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hypopituitarism","organSystem":"Endocrine disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hypothalamo-pituitary disorder","organSystem":"Endocrine disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Lymphocytic hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Retinal vascular disorder","organSystem":"Eye disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Anal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Autoimmune pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Colitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":358},{"groupId":"EG001","numAffected":3,"numAtRisk":349}]},{"term":"Duodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Incarcerated inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Large intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":358},{"groupId":"EG001","numAffected":4,"numAtRisk":349}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Rectal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":358},{"groupId":"EG001","numAffected":6,"numAtRisk":349}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":358},{"groupId":"EG001","numAffected":5,"numAtRisk":349}]},{"term":"Illness","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":358},{"groupId":"EG001","numAffected":3,"numAtRisk":349}]},{"term":"Polyserositis","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Sudden cardiac death","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cholangitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cholestasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hepatic cytolysis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hydrocholecystis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Contrast media reaction","organSystem":"Immune system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Abdominal infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Abscess jaw","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Arthritis infective","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Beta haemolytic streptococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Brain abscess","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Catheter site infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":3,"numAtRisk":349}]},{"term":"Clostridial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Coronavirus pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Dengue fever","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Diverticulitis intestinal perforated","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Escherichia infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Gastroenteritis norovirus","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Gastrointestinal infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Infective spondylitis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Mastoiditis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pneumocystis jirovecii infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":358},{"groupId":"EG001","numAffected":23,"numAtRisk":349}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Pneumonia fungal","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Pseudomonas infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":5,"numAtRisk":349}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":5,"numAtRisk":349}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Urethritis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Vascular device infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Craniofacial fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"General physical condition abnormal","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Haematocrit decreased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":3,"numAtRisk":349}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":358},{"groupId":"EG001","numAffected":5,"numAtRisk":349}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Fistula","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Hypercreatinaemia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Osteitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Lymphangiosis carcinomatosa","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":61,"numAtRisk":358},{"groupId":"EG001","numAffected":78,"numAtRisk":349}]},{"term":"Metastases to adrenals","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Plasma cell myeloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Second primary malignancy","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Squamous cell carcinoma of the tongue","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Agraphia","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Dementia Alzheimer's type","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Encephalitis autoimmune","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Immune-mediated encephalitis","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Medullary compression syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Motor dysfunction","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Quadriplegia","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"VIth nerve disorder","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Device dislocation","organSystem":"Product Issues","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":358},{"groupId":"EG001","numAffected":6,"numAtRisk":349}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Immune-mediated nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Acquired hydrocele","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Balanoposthitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":3,"numAtRisk":349}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":358},{"groupId":"EG001","numAffected":11,"numAtRisk":349}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":358},{"groupId":"EG001","numAffected":4,"numAtRisk":349}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":358},{"groupId":"EG001","numAffected":4,"numAtRisk":349}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":358},{"groupId":"EG001","numAffected":5,"numAtRisk":349}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Pulmonary artery compression","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":358},{"groupId":"EG001","numAffected":5,"numAtRisk":349}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Skin toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Stevens-Johnson syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Peripheral artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Shock haemorrhagic","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":358},{"groupId":"EG001","numAffected":1,"numAtRisk":349}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":358},{"groupId":"EG001","numAffected":0,"numAtRisk":349}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":122,"numAtRisk":358},{"groupId":"EG001","numAffected":161,"numAtRisk":349}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":358},{"groupId":"EG001","numAffected":60,"numAtRisk":349}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":358},{"groupId":"EG001","numAffected":38,"numAtRisk":349}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":358},{"groupId":"EG001","numAffected":2,"numAtRisk":349}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":61,"numAtRisk":358},{"groupId":"EG001","numAffected":12,"numAtRisk":349}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":358},{"groupId":"EG001","numAffected":22,"numAtRisk":349}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":358},{"groupId":"EG001","numAffected":17,"numAtRisk":349}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":85,"numAtRisk":358},{"groupId":"EG001","numAffected":83,"numAtRisk":349}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":111,"numAtRisk":358},{"groupId":"EG001","numAffected":68,"numAtRisk":349}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":120,"numAtRisk":358},{"groupId":"EG001","numAffected":146,"numAtRisk":349}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":71,"numAtRisk":358},{"groupId":"EG001","numAffected":61,"numAtRisk":349}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":112,"numAtRisk":358},{"groupId":"EG001","numAffected":96,"numAtRisk":349}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":358},{"groupId":"EG001","numAffected":8,"numAtRisk":349}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":81,"numAtRisk":358},{"groupId":"EG001","numAffected":62,"numAtRisk":349}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":358},{"groupId":"EG001","numAffected":10,"numAtRisk":349}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":358},{"groupId":"EG001","numAffected":37,"numAtRisk":349}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":358},{"groupId":"EG001","numAffected":39,"numAtRisk":349}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":358},{"groupId":"EG001","numAffected":9,"numAtRisk":349}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":358},{"groupId":"EG001","numAffected":14,"numAtRisk":349}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":358},{"groupId":"EG001","numAffected":8,"numAtRisk":349}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":358},{"groupId":"EG001","numAffected":11,"numAtRisk":349}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":358},{"groupId":"EG001","numAffected":21,"numAtRisk":349}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":38,"numAtRisk":358},{"groupId":"EG001","numAffected":17,"numAtRisk":349}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":358},{"groupId":"EG001","numAffected":14,"numAtRisk":349}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":358},{"groupId":"EG001","numAffected":23,"numAtRisk":349}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":358},{"groupId":"EG001","numAffected":25,"numAtRisk":349}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":358},{"groupId":"EG001","numAffected":9,"numAtRisk":349}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":358},{"groupId":"EG001","numAffected":12,"numAtRisk":349}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":358},{"groupId":"EG001","numAffected":18,"numAtRisk":349}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":38,"numAtRisk":358},{"groupId":"EG001","numAffected":22,"numAtRisk":349}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":112,"numAtRisk":358},{"groupId":"EG001","numAffected":88,"numAtRisk":349}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":358},{"groupId":"EG001","numAffected":7,"numAtRisk":349}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":358},{"groupId":"EG001","numAffected":29,"numAtRisk":349}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":358},{"groupId":"EG001","numAffected":27,"numAtRisk":349}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":358},{"groupId":"EG001","numAffected":15,"numAtRisk":349}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":358},{"groupId":"EG001","numAffected":23,"numAtRisk":349}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":358},{"groupId":"EG001","numAffected":21,"numAtRisk":349}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":358},{"groupId":"EG001","numAffected":35,"numAtRisk":349}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":55,"numAtRisk":358},{"groupId":"EG001","numAffected":36,"numAtRisk":349}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":358},{"groupId":"EG001","numAffected":16,"numAtRisk":349}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":358},{"groupId":"EG001","numAffected":17,"numAtRisk":349}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":358},{"groupId":"EG001","numAffected":21,"numAtRisk":349}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":42,"numAtRisk":358},{"groupId":"EG001","numAffected":33,"numAtRisk":349}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":358},{"groupId":"EG001","numAffected":19,"numAtRisk":349}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":358},{"groupId":"EG001","numAffected":10,"numAtRisk":349}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":358},{"groupId":"EG001","numAffected":13,"numAtRisk":349}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":68,"numAtRisk":358},{"groupId":"EG001","numAffected":45,"numAtRisk":349}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":67,"numAtRisk":358},{"groupId":"EG001","numAffected":54,"numAtRisk":349}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":358},{"groupId":"EG001","numAffected":11,"numAtRisk":349}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":358},{"groupId":"EG001","numAffected":3,"numAtRisk":349}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":358},{"groupId":"EG001","numAffected":19,"numAtRisk":349}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":358},{"groupId":"EG001","numAffected":36,"numAtRisk":349}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":358},{"groupId":"EG001","numAffected":6,"numAtRisk":349}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":85,"numAtRisk":358},{"groupId":"EG001","numAffected":11,"numAtRisk":349}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":76,"numAtRisk":358},{"groupId":"EG001","numAffected":16,"numAtRisk":349}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":358},{"groupId":"EG001","numAffected":5,"numAtRisk":349}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@bms.com","phone":"Please Email"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-05-10","uploadDate":"2020-08-15T11:05","filename":"Prot_000.pdf","size":4400220},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-08-06","uploadDate":"2020-08-15T11:30","filename":"SAP_001.pdf","size":751371}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2020-09-01","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000074324","term":"Ipilimumab"},{"id":"D000077594","term":"Nivolumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"}]}},"hasResults":true}